Read by QxMD icon Read

Bone scans in prostate cancer

Nur-Vaizura Mohamad, Muhammad Afiq Amani Che Zulkepli, Krystine May Theseira, Norain Zulkifli, Nur Quraisha Shahrom, Nurul Amni Mohamad Ridzuan, Nor Aini Jamil, Ima-Nirwana Soelaiman, Kok-Yong Chin
Introduction: Orchidectomy is currently the preferred method to induce bone loss in preclinical male osteoporosis model. Gonadotropin-releasing hormone (GnRH) agonists used in prostate cancer treatment can induce testosterone deficiency but its effects on bone in preclinical male osteoporosis model are less studied. Objective: This study aimed to evaluate the skeletal effect of buserelin (a GnRH agonist) in male rats and compare it with orchidectomy. Methods: Forty-six three-month-old male Sprague-Dawley rats were divided into three experimental arms...
2018: International Journal of Medical Sciences
Colleen Bailey, David J Collins, Nina Tunariu, Matthew R Orton, Veronica A Morgan, Thorsten Feiweier, David J Hawkes, Martin O Leach, Daniel C Alexander, Eleftheria Panagiotaki
Purpose: To examine the usefulness of rich diffusion protocols with high b -values and varying diffusion time for probing microstructure in bone metastases. Analysis techniques including biophysical and mathematical models were compared with the clinical apparent diffusion coefficient (ADC). Methods: Four patients were scanned using 13 b -values up to 3,000 s/mm2 and diffusion times ranging 18-52 ms. Data were fitted to mono-exponential ADC, intravoxel incoherent motion (IVIM), Kurtosis and Vascular, extracellular, and restricted diffusion for cytometry in tumors (VERDICT) models...
2018: Frontiers in Oncology
Anna Maria Mangano, Massimiliano Pacilio, Pasquale Ialongo, Alessandro Semprebene, Guido Ventroni, Lucio Mango
Here, we present the case of a 64-year-old male patient diagnosed with castration-resistant prostate cancer (CRPC) with bone metastasis, treated with abiraterone prednisone/prednisolone in combination with223 Ra-dichloride therapy, who had remission and a subsequent relapse of bone metastasis on repeated bone scans after therapy. We also discuss the possibility of continuing the223 Ra-dichloride therapy over the six planned administrations by administering other cycles at the same dose or at higher doses, if shown to be devoid of a significant increase in side effects, based on dosimetry considerations...
February 27, 2018: Diagnostics
Hugo Enrique Solis Lara, Natalia Villarreal Del Bosque, Miguel Antonio Sada Treviño, Masao Yamamoto Ramos, Rocío Del Carmen Argueta Ruiz
A 79-year-old man with prostate cancer underwent Ga prostate-specific membrane antigen (Ga-PSMA) dual-time-point PET/CT scan to evaluate tumor activity due to early satiety, unquantified weight loss, and elevation of prostate-specific antigen (PSA), demonstrating thickening of the gastric wall with intense tracer uptake. The immunohistochemistry of gastric biopsy showed CDX2 and CK20: negative; CK7, focal positive; PSA, positive, which confirmed metastatic disease. Metastatic disease was also found in bones, right lung, and retroperitoneal and pelvic lymphadenopathies...
February 27, 2018: Clinical Nuclear Medicine
Mohsen Beheshti, Zeinab Paymani, Joana Brilhante, Hans Geinitz, Daniela Gehring, Thomas Leopoldseder, Ludovic Wouters, Christian Pirich, Wolfgang Loidl, Werner Langsteger
PURPOSE: In this prospective study, we evaluated the optimal time-point for68 Ga-PSMA-11 PET/CT acquisition in the assessment of prostate cancer. We also examined, for the first time the feasibility of tracer production using a PSMA-11 sterile cold-kit in the clinical workflow of PET/CT centres. METHODS: Fifty prostate cancer patients (25 staging, 25 biochemical recurrence) were enrolled in this study. All patients received an intravenous dose of 2.0 MBq/kg body weight68 Ga-PSMA-11 prepared using a sterile cold kit (ANMI SA, Liege, Belgium), followed by an early (20 min after injection) semi-whole-body PET/CT scan and a standard-delay (100 min after injection) abdominopelvic PET/CT scan...
February 23, 2018: European Journal of Nuclear Medicine and Molecular Imaging
James R Ballinger
Although use of the term "theranostic" is relatively recent, the concept goes back to the earliest days of nuclear medicine, with the use of radioiodine for diagnosis and therapy of benign and malignant thyroid disease being arguably the most successful molecular radiotherapy in history. A diagnostic scan with123 I-,124 I-, or a low activity of131 I-iodide is followed by therapy with high activity131 I-iodide. Similarly, adrenergic tumours such as phaeochromocytoma and neuroblastoma can be imaged with123 I-metaiodobenzylguanidine (MIBG) and treated with131 I-MIBG...
February 23, 2018: British Journal of Radiology
Randi Fuglsang Fonager, Helle Damgaard Zacho, Niels Christian Langkilde, Joan Fledelius, June Anita Ejlersen, Helle Westergreen Hendel, Christian Haarmark, Mette Moe, Jesper Carl Mortensen, Mads Ryø Jochumsen, Lars Jelstrup Petersen
AIM: To compare18 F-sodium fluoride positron emission tomography/computed tomography (NaF PET/CT) and99m Tc-labelled diphosphonate bone scan (BS) for the monitoring of bone metastases in patients with prostate cancer undergoing anti-cancer treatment. MATERIAL AND METHODS: Data from 64 patients with prostate cancer were included. The patients received androgen-deprivation therapy (ADT), next-generation hormonal therapy (NGH) or chemotherapy. The patients had a baseline scan and 1-3 subsequent scans during six months of treatment...
February 15, 2018: Acta Oncologica
Christian Schmidkonz, Michael Cordes, Michael Beck, Theresa Ida Goetz, Daniela Schmidt, Olaf Prante, Tobias Bäuerle, Michael Uder, Bernd Wullich, Peter Goebell, Torsten Kuwert, Philipp Ritt
BACKGROUND: Tc-MIP-1404 (Progenics Pharmaceuticals, Inc, New York, NY) is a novel ligand binding to prostate-specific membrane antigen suitable for SPECT. There are, as yet, no data concerning its use in whole-body primary staging and its interobserver variability in patients with prostate cancer (PC) prior to therapy. METHODS: A search of our clinical database from April 2013 to May 2017 yielded 93 patients with histologically confirmed cancer in whom Tc-MIP-1404 SPECT/CT had been performed for primary whole-body staging before therapy...
February 3, 2018: Clinical Nuclear Medicine
Gary J R Cook, Gurdip K Azad, Benjamin P Taylor, Eugene Lee, Matthew S Morrison, Simon Hughes, Stephen Morris, Sarah Rudman, Simon Chowdhury, Vicky Goh
PURPOSE: Osteoclast activity is an important factor in the pathogenesis of skeletal metastases and is a potential therapeutic target. This study aimed to determine if selective uptake of 99mTc-maraciclatide, a radiopharmaceutical targeting αvβ3 integrin, occurs in prostate cancer (PCa) bone metastases and to observe the changes following systemic therapy. METHODS: The study group comprised 17 men with bone-predominant metastatic PCa who underwent whole-body planar and single-photon emission computed tomography/computed tomography (SPECT/CT) imaging with 99mTc-maraciclatide before (n = 17) and 12 weeks after (n = 11) starting treatment with abiraterone...
February 2, 2018: European Journal of Nuclear Medicine and Molecular Imaging
Laura Evangelista, Lea Cuppari, Andrea Guttilla, Mario Gardi, Andrea Agostini, Lorenzo Ruggera, Umberto Basso, Giorgio Saladini
PURPOSE: The aim of this study was to assess the ability of fluorine-18-fluorocholine (F-FCH) PET/computed tomography (CT) to detect oligometastatic disease (OMD) in patients with early recurrence of prostate cancer (PC) [prostate-specific antigen (PSA)≤5 ng/ml]. PATIENTS AND METHODS: Between 2010 and 2016, 324 patients with PC and PSA levels of less than or equal to 5 ng/ml were recruited. The mean (SD) age of the patients was 71 (10) years. All patients were treated with a radical prostatectomy±lymphadenectomy...
January 29, 2018: Nuclear Medicine Communications
Hendrik Rathke, Ali Afshar-Oromieh, Frederik L Giesel, Christophe Kremer, Paul Flechsig, Sabine Haufe, Walter Mier, Tim Holland-Letz, Maximilian de Bucourt, Thomas Armor, John Babich, Uwe Haberkorn, Clemens Kratochwil
To evaluate the detection rate of bone metastases obtained with the PSMA targeting tracer 99mTc-MIP-1427 as opposed to the conventional bone scan with 99mTc-MDP in a collective of advanced stage patients with known osseous metastasized prostate cancer. Methods: 21 Patients with known metastatic disease were staged with both, conventional bone scan and PSMA-ligand scintigraphy, within a time-frame of <10 days. Imaging included planar whole-body scans and SPECT or SPECT/CT with two bed positions 3 h after injection of either 500-750 MBq 99mTc-MIP-1427 or 600-750 MBq 99mTc-MDP...
January 25, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Christos Sachpekidis, P Bäumer, K Kopka, B A Hadaschik, M Hohenfellner, A Kopp-Schneider, U Haberkorn, A Dimitrakopoulou-Strauss
PURPOSE: The aims of this retrospective analysis were to compare 68Ga-PSMA PET findings and low-dose CT findings (120 kV, 30 mA), and to obtain semiquantitative and quantitative 68Ga-PSMA PET data in patients with prostate cancer (PC) bone metastases. METHODS: In total, 152 PET/CT scans from 140 patients were evaluated. Of these patients, 30 had previously untreated primary PC, and 110 had biochemical relapse after treatment of primary PC. All patients underwent dynamic PET/CT scanning of the pelvis and lower abdomen as well as whole-body PET/CT with 68Ga-PSMA-11...
January 23, 2018: European Journal of Nuclear Medicine and Molecular Imaging
A B Rutledge, N McLeod, N Mehan, T W Regan, P Ainsworth, P Chong, T Doyle, M White, R W Sanson-Fisher, J M Martin
OBJECTIVES: To improve imaging utilisation and reduce the widespread overuse of staging investigations, in the form of computed tomography (CT) and whole body bone scan (BS), for men with newly diagnosed prostate cancer in the Hunter region of NSW, Australia by implementation of a multifaceted clinician-centred behaviour change program. SUBJECTS AND METHODS: Records of all men with a new diagnosis of prostate cancer were reviewed prior to intervention (July 2014-July 2015), and results of this audit presented to participating urologists by a clinical champion...
January 23, 2018: BJU International
Yazan Z Alabed
A 76-year-old man with metastatic prostate cancer and back pain was referred for palliative radiotherapy. Staging F-fluorocholine PET/CT scan revealed fluorocholine-avid prostate mass, extensive lymphadenopathy, lung nodules, and extensive osteolytic lesions throughout the axial skeleton. Prostate cancer bone metastases are predominantly sclerotic in nature. We present F-fluorocholine PET/CT imaging of prostate cancer with very rare lytic bone metastases.
January 19, 2018: Clinical Nuclear Medicine
Matthew S Brown, Grace Hyun J Kim, Gregory H Chu, Bharath Ramakrishna, Martin Allen-Auerbach, Cheryce P Fischer, Benjamin Levine, Pawan K Gupta, Christiaan W Schiepers, Jonathan G Goldin
A clinical validation of the bone scan lesion area (BSLA) as a quantitative imaging biomarker was performed in metastatic castration-resistant prostate cancer (mCRPC). BSLA was computed from whole-body bone scintigraphy at baseline and week 12 posttreatment in a cohort of 198 mCRPC subjects (127 treated and 71 placebo) from a clinical trial involving a different drug from the initial biomarker development. BSLA computation involved automated image normalization, lesion segmentation, and summation of the total area of segmented lesions on bone scan AP and PA views as a measure of tumor burden...
January 2018: Journal of Medical Imaging
Lars J Petersen, Jesper Strandberg, Louise Stenholt, Martin B Johansen, Helle D Zacho
Bone scintigraphy is key in imaging skeletal metastases in newly diagnosed prostate cancer. Unfortunately, a notable proportion of scans are not readily classified as positive or negative but deemed indeterminate. The extent of reporting of indeterminate bone scans and how such scans are handled in clinical trials are not known. A systematic review was conducted using electronic databases up to October 2016. The main outcome of interest was the reporting of indeterminate bone scans, analyses of how such scans were managed, and exploratory analyses of the association of study characteristics and the reporting of indeterminate bone scan results...
January 16, 2018: Diagnostics
Kaoru Maruyama, Keita Utsunomia, Takahiro Nakamoto, Shigenari Kawakita, Takashi Murota, Noboru Tanigawa
A 76-year-old man with symptomatic bone metastases from castration-resistant prostate cancer underwent Radium-223-dichloride (Ra-223) therapy. Before Ra-223 therapy, he had normal peripheral blood cell counts. Ra-223 therapy relieved his shoulder and low back pain. The elevation of the serum prostate-specific antigen (PSA), doubling every month during Ra-223 therapy, suggested a PSA flare or relapse. Some lesions showed decrease and some lesions showed increase on Tc-99m hydroxymethylene diphosphonate bone scintigraphy at two weeks after the third injection of Ra-223 therapy...
2018: Asia Oceania Journal of Nuclear Medicine & Biology
Kim N Chi, Andrew Protheroe, Alfredo Rodríguez-Antolín, Gaetano Facchini, Henrik Suttman, Nobuaki Matsubara, Zhangqun Ye, Bhumsuk Keam, Ronaldo Damião, Tracy Li, Kelly McQuarrie, Bin Jia, Peter De Porre, Jason Martin, Mary B Todd, Karim Fizazi
BACKGROUND: In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostate cancer. Understanding the effects of treatments on patient-reported outcomes (PROs) and health-related quality of life (HRQOL) is important for treatment decisions; therefore we aimed to analyse the effects of ADT plus abiraterone acetate and prednisone versus ADT plus placebos on PROs and HRQOL in patients in the LATITUDE study...
January 8, 2018: Lancet Oncology
Eva Dyrberg, Emil L Larsen, Helle W Hendel, Henrik S Thomsen
Background Patient acceptance is an important factor when implementing imaging methods in clinical practice in line with availability, diagnostic accuracy, and cost-effectiveness. Purpose To investigate patient experience and acceptance regarding18F-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT), 11 C-choline-PET/CT, whole-body magnetic resonance imaging (WB-MRI), and 99mTc-hydroxymethane diphosphonate (HDP) single photon emission/computed tomography (SPECT/CT). Material and Methods One hundred and forty-nine patients with prostate cancer filled in a questionnaire regarding their experience of the imaging procedures they had been undergoing as part of a diagnostic accuracy study...
January 1, 2018: Acta Radiologica
Alicia Katherine Morgans
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
February 20, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"